[Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients].
In developed countries, where the mother-to-child transmission rate of HIV is low (1 to 1,5%), a major medical concern is the safety of new therapies during pregnancy. Teratogenicity has been described with an NNRTI, efavirenz (Sustiva), in animal model, regarding neural tube defects. We have made a retrospective study of pregnancies starting with efavirenz with a special focus on foetal and infant abnormalities. Three abnormalities were notified no one linked to a neural tube defect. In the English literature published, although the prevalence of abnormalities in human is low (1,7%) during pregnancy, due to the potent teratogenicity, efavirenz is contraindicated in the first trimester and should be used with caution in women of childbearing potential.